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Case presentation
A 45-year-old white woman came to the Emergency Room at
the Hospital Universitario de Caracas complaining of acute,
severe, upper back pain after lifting a heavy object. A radiograph
of the thoracic spine demonstrated a crush fracture of the 10th
dorsal vertebra, with skeletal demineralization in the rest of the
spine, accentuation of some vertebral end-plate shadows, and
"ballooning" intervertebral disks (Schmorl's nodes). A plain
abdominal radiograph revealed similar changes in the lumbar
vertebrae as well as bilateral renal stones (three).
At age 23, she had been hospitalized with renal colic. At that
time, a right ureterolithotomy was performed. During the ensuing
22 years, she passed approximately 25 stones, and she required
two cystoscopic procedures and one lithotripsy treatment for
removal of stones. The patient had regular menstrual periods,
denied smoking, consumed alcohol occasionally, and exercised
mildly (she walked approximately 30 minutes daily). Her father
and one sister have passed renal stones of unknown type. She was
repeatedly advised by several physicians to curtail her dietary
calcium intake substantially and she had done so; her calcium
intake was estimated to be around 550 mg/day. Crystallographic
analysis performed on one kidney stone revealed 100% calcium
oxalate dihydrate crystals (Wedelite).
On physical examination, she was in no acute distress and had
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no overt physical disabilities. Her weight was 59 kg; height, 155
cm; blood pressure, 125/82 mm Hg; heart rate, 80 beats/mm; and
respiratory rate, 15 breaths/mm. The rest of the physical exami-
nation was normal except that she experienced pain during
examination of the lower dorsal spine. Serum concentrations of
calcium, uric acid, and creatinine were normal. Two 24-hour urine
samples were collected. Average creatinine clearance was 122.5
mi/mm. Urinary calcium excretion averaged 540 mg/24 hours
(9.14 mg/kg/day). Urinary sodium excretion was high (275 mEq/
day). Uric acid excretion was normal (450 mg/day) with an
undissociated uric acid concentration within normal limits; ox-
alate excretion also was normal. Urinary citrate excretion was low
(200 mg/day) and an ammonium chloride acidification test was
normal. Urinary hydroxyproline excretion (51.3 mg/day) exceeded
the upper limit of normal, and serum osteocalcin levels were
normal. Intact total parathyroid hormone levels and urinary cyclic
AMP excretion were within the normal range. The tubular
reabsorption of phosphorus was normal. Blood estrogen levels
and thyroid functional tests were normal. Occult malignancies
including myeloma were not detected.
A dual x-ray bone absorptiometiy of the lumbar spine (trabec-
ular bone) revealed a bone mineral density of 0.625 g/cm2 (Z
score: —2.85); at the femoral neck (cortical bone), bone mineral
density was 0.690 g/cm2 (Z score: —1.32); total body mineral
density was 0.865 g/cm2 (Z score: —1.1).
The patient was advised to reduce her sodium intake to 120
mEq/day, to maintain a calcium intake of approximately 900
mg/day, and to drink at least 3 liters of fluid daily. A thiazide
diuretic and potassium citrate were prescribed. After 2 months on
this regimen, her urinary calcium had decreased to 180 mg/24
hours (3.05 mg/kg/day), and urinary citrate excretion had in-
creased to 432.5 mg/day. The patient has passed no stones in the
19 months since beginning this regimen.
Discussion
DR. JosÉ R. WEISINGER (Director, Division of Nephrology and
Kidney Transplantation, Hospital Universitario de Caracas, and
Professor of Medicine, Universidad Central de Venezuela, Caracas,
Venezuela): This premenopausal woman with premature osteopo-
rosis, a crush vertebral fracture, and recurrent renal calculi
illustrates one of the main iatrogenic problems in the manage-
ment of renal stones, namely, the restriction of dietary calcium in
idiopathic hypercalciuria. Primary hyperparathyroidism and re-
sorptive hypercalciuria due to malignant disease were ruled out,
and idiopathic hypercalciuria with a substantial calcium leak,
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Table 1. Incidence of metabolic abnormalities among 2690 patients
with renal stones seen at the University Hospital of Caracas, 1982—1 994
Number Percentage
Idiopathic hypercalciuria 1214 45.1
Hyperuricosuria 506 18.8
Hypocitraturia 384 14.3
Primary hyperparathyroidism 114 4.2
Hyperoxaluria 78 2.9
Distal tubular acidosis 58 2.2
Cystinuria 6 0.2
No identifiable metabolic abnormalities 330 12.3
persistent negative calcium balance, and bone resorption was
diagnosed. A reduction in dietary calcium intake, generalized
practice in the management of renal stone disease, did not
prevent the recurrence of renal stones. Unfortunately, it even
might have further aggravated her osteoporosis. Before analyzing
this controversial therapeutic maneuver, let me first discuss
several aspects about the incidence and pathophysiology of uro-
lithiasis.
Epidemiology of renal stones
Nephrolithiasis, a common clinical disorder, affects 1% to 5%
of the general population, with an annual incidence of 0.1% to
0.3% [1, 2]. In certain areas, especially in the Caribbean and
northern part of South America, the incidence appears to be
much higher [31. This higher incidence could be related to
heredity, diet, and environmental factors [4, 5]. In several un-
selected population surveys, the lifetime risk for stone formation
in the adult white man approaches 20%; for women, it approxi-
mates 5% to 10% [6]. A recent report on demographic and
geographic variablity of renal stones in the United States showed
an increased prevalence with age until age 70, and a higher
incidence in men than in women and in whites than in blacks [7].
Stone composition is heterogeneous, depending on the underlying
pathophysiologic mechanisms involved in its origin. Innumerable
chemical, physical, physicochemical, physiologic, and biochemical
events are involved in crystal formation and growth. Most stones,
however, contain calcium in the form of calcium oxalate, hydroxy-
apatite and, less frequently, brushite.
Although much progress has been made in the elucidation and
management of nephrolithiasis during the past two decades, and
despite the fact that it is now possible to detect the underlying
metabolic alteration in the majority of patients, controversies still
exist about the definite pathophysiologic events responsible for
this condition. It seems evident that stone formation results from
an imbalance in the urine between factors that promote crystalli-
zation and those that inhibit crystal formation and growth [8, 9].
The oversaturation of urine with calcium is generally agreed to be
one of the most important risk factors for calcium nephrolithiasis.
Calcium oversaturation promotes stone formation by different
mechanisms, including saturation of urine with respect to calcium
oxalate and calcium phosphate [101. In addition, calcium binds to
inhibitors of crystallization such as citrate and glycosaminogly-
cans, thus reducing their inhibitory activity [11].
Table 1 shows the incidence of the different metabolic abnor-
malities in 2690 patients screened in our laboratory during the last
12 years. Idiopathic hypercalciuria was the primary metabolic
alteration in almost one-half of the patients. Hypercalciuria was
defined as a 24-hour urinary excretion of calcium, in two consec-
utive collections, that exceeded 4 mg/kg/day, or 140 mg per gram
of creatinine [12—14]. The diagnosis of idiopathic hypercalciuria is
established after ruling out the known systemic diseases that cause
normocalcemic hypercalciuria [15].
Pathogenesis of hypercalciuria
Binary theory of hypercalciuria. The association of hypercalciuria
with calcium stones was first recognized in 1939 by Flocks [16].
Fourteen years later, Albright et al described a group of patients
with hypercalciuria, normal serum calcium, and a history of
recurrent passage of calcium-containing renal stones [171. The
cause of the hypercalciuria was unknown, and the term "idiopath-
ic hypercalciuria" was adopted. The first major breakthrough in
our understanding of the pathophysiology of this entity came in
1974 when Pak and colleagues stratified this condition into two
subtypes [18]. The first subtype, initially called "reabsorptive" or
"renal hypercalciuria" and later renamed "fasting hypercalciuria,"
was thought to represent a renal calcium leak that triggered a
compensatory increase in PTH secretion, increased production of
1,25(OH)2D3 (calcitriol), and increased gastrointestinal calcium
absorption. The second subtype, "absorptive hypercalciuria," was
defined as a primary intestinal hyperabsorption of calcium. This
subtype was diagnosed by the absence of fasting hypercalciuria, an
increased hyperabsorption of calcium after the so-called "calcium
absorption test" following one week of a low-calcium diet, and a
low circulating PTH level [191.
This pathophysiologic classification initially appeared very ap-
pealing because of its simplicity and practical therapeutic impli-
cations. Thus, a low-calcium diet or sodium cellulose phosphate
was advocated for the absorptive type [20], whereas an oral
thiazide diuretic agent was employed for renal or fasting hyper-
calciuria [21].
Disordered regulation of 1,25(OH)2D3. Pak's classification
schema remained unchallenged until 1982, when Coe and col-
leagues studied normal subjects and hypercalciuric patients who
were following a very-low-calcium diet (2 mg/kg/day) [22]. These
researchers suggested that familial hypercalciuria was due to a
disordered regulation of 1,25(OH)2D3, probably related to an
inherited abnormality of the renal proximal tubule that led to
abnormal 1,25(OH)2D3 regulation [22, 23]. The authors argued
that this abnormality was present in the majority of patients, as
excess calcitriol production was shown to induce intestinal calcium
absorption and reduce tubular reabsorption of calcium, and to
result in normocalcemic hypercalciuria. However, studies in ge-
netically hypercalciuric rats [24] and in patients with renal stones
[25] suggested that other factors besides disordered regulation of
1,25(OH)2D3 were involved in the pathogenesis of hypercalciuria.
More recently, Li et a! demonstrated that hypercalciuric rats have
an increased number of intestinal vitamin D receptors (VDR) and
normal levels of circulating 1,25(OH)2D3, and that the excess
VDRs result in increased functional VDR-1,25(OH)2D3 com-
plexes and increased intestinal calcium transport in enterocytes
[26].
To evaluate the possibility of an increased sensitivity to
I ,25(OH)2D3, we studied a group of 21 normal subjects and 72
consecutive calcium-stone formers who underwent metabolic
evaluation; these data were reported in a recent text on urolithi-
asis [27]. Of the 72, 48 patients were hypercalciuric and 24 were
normocalciuric. Subjects were studied during three experimental
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Fig. 1. Effects of one week of calcium restriction(column B) and calcium restriction + I pg/day
of orally administered l,25(OH)2D3 for another
week (column C), on the urinary excretion of
calcium in normal subjects (N = 21) and
calcium oxalate stone jbrmers with evidence of
normocalciuria (N 24) or hypercalciuria (N
48). Calcium excretion is expressed as mg of
urinary calcium/I 00 ml of glomerular filtrate. A
is normal diet, B is low-calcium diet, C is low-
calcium diet + 1,25(OH)2D3. (Modified from
Ref. 27.)
conditions: normal calcium intake, a very-low-calcium diet (2
mg/kg/day), and an equally low-calcium diet supplemented with
1,25(OH)2D3 (1 jig/day). As expected, on a normal calcium diet,
hypercalciuric patients excreted more calcium than did normocal-
ciuric stone formers and healthy controls. After one week of the
calcium-restricted diet, both the control and normocalciuric
groups had a significant decrease in urinary calcium excretion; the
urinary calcium level remained unchanged in the hypercalciuric
stone formers, however (Fig. 1). Also, after taking oral
1,25(OH)2D3 for one week, the controls and normocalciuric stone
formers showed an increase in urinary calcium excretion; hyper-
calciuric subjects did not. In addition, in controls and normocal-
ciuric stone formers, exogenous administration of 1,25(OH)2D3
increased intestinal calcium absorption, as assessed indirectly by
the change in the fractional urinary excretion of calcium after an
oral calcium load. In hypercalciuric patients who showed in-
creased intestinal calcium absorption under the normal- and
low-calcium diet, I,25(OH)2D5 administration did not increase
urinary calcium further. Interestingly, serum levels of calcium and
1,25(OH)2D3 before and after administration of the hormone
were similar in all groups. These preliminary studies suggest that
hypercalciuric patients do not have an increased sensitivity to
1,25(OH)2D3 and that perhaps other factors are involved in the
pathogenesis of this entity. Nevertheless, the possibility that the
patients were maximally stimulated by the endogenous
1,25(OH)2D3, and that exogenous 1,25(OH)2D3 does not induce
further calcium absorption, could not he excluded.
Role of parathyroid hormone. Primary hyperparathyroidism has
been considered an important cause of calcium nephrolithiasis
[28]. However, in recent series, it accounted for only a small
fraction of patients. In our group, primary hyperparathyroidism
was observed in only 4.3% of the patients. This small fraction of
patients has hypercalcemia, elevated serum immunoreactive PTH,
and fasting hypercalciuria, the result of bone resorption and a
consequent increase in the filtered load of calcium. In addition,
these patients exhibit high fractional urinary calcium excretion
after an acute calcium load, possibly secondary to PTH-dependent
stimulation of 1,25(OH)2D3 synthesis, as suggested by Broadus
and colleagues [29]. The role of PTH in the pathogenesis of
idiopathic hypercalciuria thus remains unclear. As I said, in
patients with a primary calcium leak, the negative calcium balance
could conceivably lead to secondary hyperparathyroidism. Con-
versely, in patients with primary intestinal hyperabsorption, PTH
secretion is likely suppressed.
Whether PTH blood levels are altered in patients with idio-
pathic hypercalciuria remains controversial. Normal and subnor-
mal levels of PTH have been found in patients with different types
of idiopathic hypercalciuria [30]. Few patients with fasting hyper-
calciuria have elevated levels of PTH [311. However, we must
interpret these data cautiously, because each PTH assay employs
antisera with antibodies directed against specific regions of the
PTH molecule and has different sensitivities for the hormone.
Thus, it is possible that in some circumstances mild elevations of
serum PTH are not detected, depending on the antiserum used.
In the kidney, PTH functions via activation of the adenylate
cyclase system at the basolateral membrane of renal cortical
tubular cells [32, 33]. As a result, cyclic AMP increases in cells and
urine. On the basis of this effect of the hormone, nephrogenous
cyclic AMP (calculated as urine cyclic AMP minus the filtered
load of cyclic AMP) has been used as an index of PTH activity
[341. Early studies by Pak et al suggested a role for PTH by
demonstrating that patients with renal hypercalciuria tend to have
higher fasting excretion of cyclic AMP than do patients with
intestinal hyperabsorption of calcium [181. More recently, Hess
and coworkers demonstrated a relative hypoparathyroidism asso-
ciated with calcitriol upregulation in hypercalciuric renal stone
formers [35].
In preliminary studies, we have examined PTH status in a group
of patients being evaluated for urinary stone disease and in
control subjects. We found that patients with hypercalciuria
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Table 2. Comparison of bone mineral and total-body mineral density in
normal and hypercalciuric children
Bone mineral density (g/cm2)
Urinaly calcium Trabecular Cortical
Number (mg/kg/day) (Spine) (Neck) TBMh
Control 11 1.16 0.52 0.65 0.04 0.75 0.11 0.87 0.12
Hypercalciuriac 21 4.73 0.94
P < 0.001
0.55 0.09 0.68 0.11
P < 0.03 NS"
0.83 0.08
NS
a Adapted from Ref. 53.
h TBM refers to total-body mineral density.
C The hypercalciuric children were matched to the controls for age,
height, gender, and weight.
"Not significant.
Fig. 2. Bone mineral density determined at the lumbar spine, femoral neck
and total body, in normal postmenopausal women (LIi; N = 818) and
postmenopausal women with previous evidence of renal stones of different
metabolic causes • N = 114). Women were similar regarding age and
time of menopause. Bone mineral density is expressed as g/cm2.
unrelated to primary hyperparathyroidism had normal or unde-
tectable PTH levels [36]. We did not find a correlation between
calcium excretion and fasting urinary cyclic AMP excretion during
ingestion of a low-calcium diet. When subjects were separated
according to their response to an oral calcium load after one week
on a low-calcium diet, patients with fasting hypercalciuria had
slightly higher levels of urinary cyclic AMP than did patients with
absorptive hypercalciuria, but the difference was not statistically
significant. In summary, there is no agreement on the existence of
secondary hyperparathyroidism in patients with idiopathic hyper-
calciuria. My own belief is that the changes that could exist in the
PTH levels are secondary and that PTI-I is not primarily involved
in the pathogenesis of idiopathic hypercalciuria.
The role of bone. In addition to either excessive intestinal
absorption of calcium, or the renal leak of calcium due to a
tubular disturbance, increased mobilization of bone calcium has
been suggested as the explanation for the hypercalciuria in
calcium oxalate renal stone formers.
More than 25 years ago, Liberman et al suggested that stone-
forming patients with idiopathic hypercalciuria suffer from a
generalized disturbance of calcium metabolism, as reflected by an
increase in the size of the miscible calcium pool, calcium turnover,
and bone formation rate [37]. They suggested that an unidentified
extra-osseous hormonal imbalance leads to high calcium turnover,
intestinal hyperabsorption, and ultimately urinary hyperexcretion
of calcium.
A decrease in bone mineral density has been reported in
patients with nephrolithiasis by photon absorptiometry of the
distal radius [38, 39] or lumbar spine [40], radiologic evaluation of
the proximal radial shaft [41], and in-vivo neutron activation
analysis and whole-body counting [42]. In addition, in evaluating
the circadian rhythm of urinary total hydroxyproline excretion,
Sutton and Walker suggested that increased bone turnover ac-
counts for the hypercalciuria in these patients [43]. In two other
studies, bone mineral density was diminished in patients with
fasting or renal hypercalciuria, but it was normal in those with
absorptive hypercalciuria [44, 45]. Patients with persistent hyper-
calciuria after a low-calcium diet showed decreased vertebral
mineral density (quantitative computed tomography), whereas
those in whom hypercalciuria was controlled by the same diet
showed normal vertebral mineral density values [46]. Results of
bone histomorphometric studies in hypercalciuric patients have
yielded conflicting results. Some have reported increased osteo-
elastic resorption accompanied by decreased osteoblastic surfaces
[7I. In a controlled study, Steiniche et al found a moderate
mineralization defect, prolonged mineralization lag, and in-
creased extension of eroded surfaces [48]. In contrast, Malluche
and coworkers noted normal or even decreased bone resorption
associated with decreased bone formation and mineralization in
patients with idiopathic absorptive hypercalciuria type I [49].
More recent studies have described significantly lower osteoblas-
tic and mineralizing surfaces in hypercalciuric men with idiopathic
osteoporosis compared with non-hypercalciuric osteoporotic
counterparts [50]. Heilberg et al reported reduced bone forma-
tion, increased bone resorption, and a severe mineralization
defect in patients with idiopathic hypercalciuria [51].
We recently analyzed cortical (femoral neck), trabecular (lum-
bar spine), and total-body bone mineral density, as determined by
dual photon absorptiometry, in a group of 114 postmenopausal
women with previous histories of renal stones of different causes,
and in 818 normal postmenopausal women (matched by age and
years since menopause, unpublished observations). The women
who had had renal stones had significantly lower total-body
mineral density as well as lower bone mineral density both at
cortical and trabecular sites (Fig. 2).
Normocalcemic hypercalciuria is an inherited trait [52, 53], so
high urinary excretion of calcium could start very early in life. To
assess whether diminished bone mass is already present during the
early stages of the disease, we analyzed bone mineral density in 21
hypercalciuric children (mean age, 9.3 2.08 years) and 11
normal controls, matched for age, gender, and height. The
hypercalciuric children demonstrated lower trabecular bone min-
eral density at the lumbar spine than did controls [54]. The
cortical bone and total bone mineral density did not differ
statistically (Table 2). The potential impact of these findings on
final peak bone mass, a major determinant of adult bone mass
[55], should be evaluated prospectively.
The critical question that remains to be answered is: Is hyper-
calciuria the result of a primary disorder of bone metabolism, or
is the decrease in bone mineralization in turn a consequence of
the hypercalciuria with its attendant negative calcium balance?
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Studies by Pacifici et a! demonstrated that monocytes from
patients with fasting hypercalciuria overproduced interleukin-l(IL-i) [561, a potent in-vivo and in-vitro stimulator of bone
resorption [57]. This abnormality was not found in patients with
absorptive hypercalciuria. However, this study was performed in
patients of both genders, who had a mean age of 46.8 years, and
obviously could have included some postmenopausal women.
Patients with high-turnover postmenopausal osteoporosis have
been shown by the same authors to produce excessive amounts of
IL-i [58, 59].
The role of this cytokine in postmenopausal bone loss has been
suggested in recent studies showing increased expression of IL-i
mRNA in bone cells from postmenopausal women [601. Other
cytokines, such as interleukin-6 (IL-6) and tumor necrosis fac-
tor-a (TNF-a), also have been shown to be involved in the bone
resorption process of different entities [61, 62]. These observa-
tions led us to further examine whether a specific member of the
IL-i family (a or /3) or other cytokines are affected in hypercal-
ciuric patients. We examined 29 patients of both sexes with
recurrent renal stones (17 hypercalciurics and 12 normocalci-
urics), and 12 healthy controls matched for gender, age, height,
and weight. All the female patients were premenopausal. Bone
mineral content and bone mineral density were measured by
dual-energy x-ray absorptiometry (Lunar DPX-L, Lunar Corpo-
ration, Madison, Wisconsin, USA). The hypercalciuric patients
showed statistically significant lower trabecular (lumbar spine)
bone mineral density than did the normocalciurics or control
subjects [631. No difference in bone mineral density was found
between patients with absorptive or fasting hypercalciuria. We
also noted a highly significant inverse correlation between urinary
calcium excretion and the Z score of trabecular bone mineral
density. Peripheral blood mononuclear cells (PBMCs) were iso-
lated from each patient by Ficoll-Hypaque gradients of hepa-
rinized venous blood. Plastic adherent cells were obtained and
cultured in complete medium over 48 hours, and the supernatants
were tested for IL-la, IL-113, IL-6, and TNF-a with a sensitive
enzyme-linked immunosorbent assay (ELISA, R&D Systems,
Minneapolis, Minnesota, USA). Our finding of a significant
correlation between in-vitro IL-la production in unstimulated
cultures of PBMCs and the Z score of the lumbar spine mineral
density (Fig. 3), suggests that increased IL-la production could
contribute to the demineralization observed in the hypercalciuric
patients. By contrast, we noted no correlation between spontane-
ous in-vitro production of IL-i/3, IL-6, or TNF-a by plastic
adherent PBMCs and the density of trabecular bone mineral.
Because we suspected that other cytokines are involved in this
process, as has been demonstrated in other metabolic bone
diseases [64, 65], we subsequently evaluated lipopolysaccharide
(LPS)-induced cytokine production in adherent PBMCs obtained
from normocalciuric and hypercalciuric stone formers and control
subjects. In this model, we found that LPS-stimulated production
of IL-la, IL-6, and TNF-a was significantly greater in the
hypercalciuric subjects compared with normocalciuric stone form-
ers or control subjects [63]. Finally, in experiments utilizing the
reverse transcriptase polymerase chain reaction, we have found
that the expression of IL-la mRNA is increased in unstimulated
blood rnonocytes obtained from hypercalciuric patients when
compared to normocalciuric stone formers or healthy controls
(Fig. 4). We have been unable to determine as yet whether the
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Fig. 3. Relationship between in-vitro IL-la production in unstimulated
cultured adherent PBMCs and the Z score of Ira becular bone mineral density
in hypercalciuric patients. Z score represents the comparison of the bone
mineral density with age-matched normal controls; r =
—0.45; P < 0.02.
(Reprinted with permission from Ref. 63.)
the IL-la gene or to stabilization of the IL-la mRNA. In
summary, these observations demonstrate increased in-vitro produc-
tion of various cytokines that might be involved in bone resorption in
patients with hypercalciuria and nephrolithiasis.
Cytokines generally are soluble molecules that instruct cells
bearing specific receptors to alter their proliferation, differentia-
tion phenotype, secretion, or rate of migration [66]. These factors
could play an important role in bone resorption in different ways:
(1) They could have a direct effect on osteoclast-mediated bone
resorption, either by direct activation or by cell recruitment [67].
Osteoclasts are derived from progenitor cells that also give rise to
circulating monocytes and tissue macrophages. The differentia-
tion of these cell progenitors requires several cytokines such as
macrophage-colony-stimulating factor (M-CSF), granulocyte-
macrophage-colony-stimulating factor (GM-CSF), and IL-6. In
turn, activated osteoblasts are able to secrete M-CSF, GM-CSF,
and IL-6 and therefore can recruit new osteoclasts.
(2) Elevated production of cytokines could increase the synthe-
sis of eicosanoids, predominantly prostaglandin E (PGE), which
exhibits bone-resorption potential. In fact, IL-i stimulates PGE
release in muscle cells [68] and dermal fibroblasts [69]. Evidence
also suggests that patients with idiopathic hypercalciuria have
increased urinary excretion of PGE [701. Furthermore, other
studies have shown that treatment with prostaglandin synthesis
inhibitors decreases calcium excretion in fasting hypercalciuric
patients [71] and in children with the hyperprostaglandin E
syndrome, a congenital condition characterized by hypercalciuria,
nephrocalcinosis, and osteopenia [72, 73].
Another factor to be considered that potentially could lead to
increased bone turnover is subtle metabolic acidosis resulting
from high dietary protein intake. This condition could lead to the
release of calcium salts from bone, as calcium carbonate acts as a
buffer [74, 75]. Oral administration of potassium bicarbonate, at a
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Fig. 4. Gel electrophoresis of IL-] a (A) and
human j3 actin (B) cDNA, amplified by RT-PCR.
Total RNA was extracted from unstimulated
PBMCs obtained from normal controls (C) and
from normocalciuric (N) and hypercalciuric (H)
stone formers. The positive control is
represented as +. (Reprinted with permission
from Ref. 63.)
dose sufficient to neutralize endogenous acid, improved calcium
and phosphorus balance and reduced bone resorption in post-
menopausal women [76]. The efficacy of this therapeutic maneu-
ver in patients with hypercalciuria (and osteoporosis) remains to
be evaluated.
Finally, as I already mentioned, idiopathic hypercalciuria can be
genetically determined [52, 53]. There is a known increase in
intestinal VDR number in hypercalciuric rats [26]. Recently,
Morrison and coworkers suggested that bone mass, a main
determinant of osteoporotic fracture, has a genetic component
ascribed largely to a simple allelic change in the vitamin D-
receptor gene [77]. These authors demonstrated that monozygotic
twins show less variation in bone mass than did dizygotic twins,
and that the main mechanism responsible for this genetic effect is
linked to polymorphism of the vitamin D-receptor gene. The
inheritance of hypercalciuria as related to the bone alterations,
and the role of the vitamin D receptor, should be addressed in
patients with idiopathic hypercalciuria.
As evident from this discussion, the pathophysiology of hyper-
calciuria cannot be explained by a single mechanism or theory.
Although mobilization of bone calcium by itself cannot be the
only cause of the hypercalciuria, we believe that bone cells
involved in bone formation and resorption play a central role in
the chain of events leading to hypercalciuria (Fig. 5). Future
studies, particularly ones employing molecular biology and ge-
netic techniques, should improve our understanding of the possi-
ble defects that contribute to the development of hypercalciuria
and nephrolithiasis.
Therapeutic implications
Whether the decrease in bone mineral mass constitutes the
primary event responsible for the hypercalciuria or is its conse-
quence, dietary calcium restriction in patients with hypercalciuria
could have deleterious effects on bone metabolism. Genetically
hypercalciuric rats subjected to a low-calcium diet continued to
excrete excessive amounts of urinary calcium and to manifest
bone-mineral loss [78]. Curhan et al prospectively evaluated the
relationship between dietary calcium intake and the risk of
symptomatic renal stones in a cohort of 45,619 men [79]. The
incidence of symptomatic renal stones during a followup of 4 years
was lower by almost 50% among the men with the highest
energy-adjusted calcium intake (1326 mg/day) compared with
those with the lowest intake (516 mg/day). These authors postu-
lated, albeit without any firm evidence, that this protective effect
of a high-calcium diet is mediated through decreased intestinal
oxalate absorption (increased dietary intake of calcium presum-
ably precipitates oxalate in the gut) with a subsequent decrease in
the relative saturation of the urine with respect to calcium oxalate.
Thus, dietary restriction of calcium not only fails to decrease
the incidence of subsequent calcium oxalate Stones, but possibly
further aggravates bone mineral loss. The latter seems particularly
of concern when treating children who have active bone mineral
accretion and women who eventually will face menopause and
postmenopausal osteoporosis.
A rational approach to the treatment of patients with hypercal-
ciuria and nephrolithiasis should include increased fluid intake,
dietary restriction of sodium and protein, the use of potassium
citrate to inhibit calcium oxalate crystallization, and the administra-
tion of thiazides or chiorthalidone for persistent hypercalciuria.
Questions and answers
DR. NIcoLAos E. MADIA5 (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): I assume that you
consider the increased cytokine production by peripheral blood
monocyte cells in patients with hypercalciuria an indicator of
increased release of cytokines by resident cells acting in an
autocrine fashion at the bone level. In this context, is there any
evidence of increased expression of cytokine genes in bone cells in
patients with hypercalciuria or in rats with genetic hypercalciuria?
DR. WEISINGER: Peripheral blood mononuclear cells removed
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Fig. 5. Hypothetical view of some of the pathophysiologic events leading to the development of hypercalciuria in renal stone formers. PBM represents
peripheral blood monocytes and VDR the vitamin-D receptor.
from healthy subjects contain little mRNA for IL-i, as determined
by Northern blot analysis [801 or the polymerase chain reaction
[81]. Nevertheless, these cells could be easily stimulated to
produce the polypeptide cytokines. Some of these cytokines,
namely IL-i and TNF, are involved in the pathogenesis of many
diseases. Clinical studies in different situations such as sepsis,
rheumatoid arthritis, Kawasaki's syndrome, and chronic hemodi-
alysis have shown circulating mononuclear cells in a state of
activation [82, 831. We think that mononuclear cells from hyper-
calciuric patients also could be in a stimulated situation resulting
in overproduction of cytokines. Nevertheless, most of the cyto-
kine-related bone resorption probably originates from cells within
the bone, either peripheral blood monocytes that have been
incorporated into bone, or primitive cells of the monocyte-
macrophage lineage that reside in bone. No data exist regarding
cytokine production by bone marrow cells or bone cells in patients
with hypercalciuria, so we will need to see studies on cytokine
gene expression by bone marrow or bone cells to support or refute
this hypothesis. Similarly, no studies in genetically hypercalciuric
rats demonstrate an increased expression of cytokine genes in
bone cells,
DR. MADIAS: I noticed the correlation between IL-icE produc-
tion by peripheral blood monocytes and the bone Z score in your
patients. Could you actually demonstrate a correlation between
IL-la production and urinary calcium excretion?
DR. WEISINGER: We found a highly significant correlation
between IL-la production by peripheral blood monocytes and the
trabecular bone Z score in our patients. No correlation was
obtained between urinary calcium and cortical (femoral neck) Z
score, however. Nor could we find any difference between the
bone mineral density Z score and the subtype of hypercalciuria
(fasting or renal hypercalciuria).
DR. MADIAS: Given your data on cytokine production and the
current evidence on the role of cytokines in postmenopausal
osteoporosis, is there clinical evidence for increased susceptibility
of hypercalciuric women to postmenopausal osteoporosis?
DR. WEISINGER: We know that estrogen loss results in a larger
secretion of IL-i by peripheral blood monocytes [58, 59] and also
in increased IL-6-mediated stimulation of osteoclastogenesis [62].
These changes suggest a role for IL-6 in increased bone resorption
in postmenopausal osteoporosis. I am not aware of any prospec-
tive study comparing the incidence of osteoporosis in postmeno-
pausal women who do or don't have idiopathic hypercalciuria. In
the retrospective study that we performed, we found that women
with a history of renal stones, most of whom followed a low-
calcium diet for many years, have decreased bone mineral mass as
compared with similar women (age, years since menopause) who
do not have renal stones. Regarding your question, it will also be
of interest to design a study to compare cytokine production by
peripheral blood monocytes, bone marrow, or bone cells from
normal and idiopathic hypercalciuric women before and after
menopause.
DR. Luis RuIL0PE (Department of Medicine, Hospital 12 de
Octubre, Madrid, Spain): Thiazide diuretics can induce metabolic
alkalosis. Changes in acid-base status could influence the balance
between bone destruction and formation. Do you think that
thiazide diuretics, besides impeding renal calcium excretion, also
could directly influence the bone by inducing metabolic alkalosis?
DR. WEISINGER: Thiazides decrease urinary calcium excretion
by augmenting calcium reabsorption in the distal tubule directly,
and by causing mild extracellular volume contraction with subse-
quent stimulation of proximal tubular reabsorption of calcium.
This correction of the hypercalciuria theoretically could restore to
normal the serum 1,25(OH)2D3 levels [84] and intestinal calcium
absorption [85]. Thiazide-diuretic-induced hypokalemia often is
accompanied by metabolic alkalosis that reflects increased urinary
hydrogen ion loss and contraction of the extracellular volume [861.
The effect of this metabolic alkalosis on bone in hypercalciuric
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patients has not yet been determined, although we know that
chronic metabolic alkalosis, at least in the experimental animal,
increases serum PTH and 1,25(OH)2D3 levels through a fall in
ionized calcium [87] that could certainly affect the bone. At the
same time, alkalosis decreases tubular citrate reabsorption and
therefore increases urinary citrate excretion.
DR. MANUEL MARTINEZ-MALDONADO (Vice-Chairman, Depart-
ment of Medicine, Emory University, Decatur, Georgia): It appears
to me that since the pathophysiologic schemes explaining hyper-
calciuria were first described, any new data have been incorpo-
rated into these schemes, which are then expanded or modified to
maintain the initial intent of the schemes. In the case of cytokines,
it seems unlikely that circulating levels of any of them are critical;
most of them work as paracrine or autocrine factors. How can
large populations of hypercalciuric patients, such as those who live
in the "stone belt" area that you described, result from peripheral
blood monocyte activation? If it were true, we would need to
propose a new disease, which induces IL-la in specific cells and
thus increases bone resorption. I suggest that we go back to the
drawing board and make clear-cut separations in what might be
new mechanisms of new diseases or modifications in our under-
standing of old ones.
DR. WEI5INGER: Many important research observations have
advanced our understanding of the pathophysiology of hypercal-
ciuria. The hypothesis suggesting a role for certain cytokines in
the pathophysiology of hypercalciuria does not intend to explain
the entire pathogenesis of this disease. I think that the term
"idiopathic hypercalciuria" will disappear as the pathophysiology
of this complex entity is elucidated. The hypercalciuria of neph-
rolithiasis comprises several entities of heterogeneous origin [88]
that eventually might be attributed to different elements of the
prevailing major theories of hypercalciuria.
DR. J. STEWART CAMERON (Clinical Science Laboratories, Guy's
Hospital, London, United Kingdom): Is it possible that the defect in
hypercalciuria is in fact a subtle deficit in renal acid excretion, with
the second factor being the extra acid from methionine in dietary
protein that results in buffering of acid in bone at the expense of
bone calcium? The analogy of gout comes to mind, in which a
kidney that reabsorbs an unusually high amount of uric acid does
not lead to gout unless stressed with a high-purine diet. If this
hypothesis were true, sodium bicarbonate would be as effective as
potassium citrate in correcting hypercalciuria. Are there any data
on hydrogen ion balance in hypercalciuric patients reminiscent of
the studies by Lemann and Relman three decades ago in chronic
renal failure?
DR. WEISINGER: Your point is well taken. We have known for
many years that recurrent calcium nephrolithiasis is associated
with distal renal tubular acidosis, with a frequency of renal
acidification defects that ranges from 0.4% to 30% in different
series. Different groups of investigators have found a defective
proximal tubular reabsorption of bicarbonate, as shown by a
reduced bicarbonate threshold, in about 47% of the patients with
recurrent calcium nephrolithiasis [89, 90]. For these reasons, one
could postulate that the acidosis present in many patients, plus the
endogenous acid production from the dietary protein catabolism,
could be responsible in part for the bone alterations that occur.
Regarding your point about the equal effectiveness of sodium
bicarbonate and potassium citrate, we know that sodium bicar-
bonate increases urinary calcium excretion when compared to
potassium bicarbonate, and leads to a persistent negative calcium
balance and potential bone loss [91]. The same result would likely
obtain when we compare the effectiveness of sodium bicarbonate
and potassium citrate.
DR. DANIEL BATLLE (Department of Medicine, Northwestern
University, Chicago, illinois): I like your recommendation of using
citrate therapy for patients with hypercalciuria, particularly be-
cause of data published only in abstract form by Dr. Rombolà and
associates in Milan, Italy, showing that the intracellular pH
measured in lymphocytes from individuals with idiopathic hyper-
calciuria is low when compared with that of normal individuals
[92]. An acidic intracellular environment could explain the re-
duced tubular calcium reabsorption and resistance to the antical-
ciuric action of PTH in a manner similar to that occurring with
experimental systemic acidosis.
DR. EDUARDO SLATOPOLSKY (Department of Medicine, Washing-
ton University School of Medicine, St. Louis, Missouri): I have a
similar comment. It is well known that metabolic acidosis in-
creases urinary calcium excretion. As a matter of fact, even in
patients who ingest different amounts of dietary protein, you can
correlate the amount of protein, the amount of protons, and the
amount of calcium that appears in the urine. So the point that you
have made about correcting the protein intake in hypercalciuric
patients is extremely important. In addition, recent data suggest
that acidosis uncouples bone formation and bone resorption [93].
DR. CAMERON: There are at least three members of the IL-i
family in monocytes: IL-la, IL-113, and IL-i receptor antagonist
(IL-ira), each coded by a related but separate gene. Whereas
IL-lp and IL-ira are normally cleared and secreted, so that they
can act in an autocrine and paracrine fashion, IL-la is not
secreted but only expressed on the surface of the cells. Do you
have any ideas on how IL-Ia might influence osteoblasts, because
this implies direct cell contact?
DR. WEIsINGER: As you mentioned, most of IL-la remains in
the cytosol of cells in its precursor form, where it functions as an
autocrine messenger. But evidence also indicates that the precur-
sor is transported and bound to the cell surface. This membrane-
bound precursor is biologically active, perhaps serving as a
paracrine messenger to adjacent cells. Evidence also suggests that
IL-i can act on isolated bone cells in vitro, triggering the
expression of the genes for collagenases as well as phospholipases
and cyclooxygenase. Another important piece of information
comes from recent work in oophorectomized rats with rapid bone
loss, in which treatment with IL-ira specifically blocked estrogen-
dependent bone resorption [94].
DR. MADIAs: Is the increased number of duodenal vitamin-D
receptors in rats with genetic hypercalciuria an isolated abnormal-
ity? What about vitamin D receptors in other target cells, such as
bone?
DR. WEISINGER: Binding analyses of VDR-1,25(OH)2D3 using
duodenal mucosa from idiopathic hypercalciuric rats demon-
strated a clear increase in the concentration of high-affinity VDR
binding sites when compared with intestinal mucosa obtained
from normal animals [26]. Also, rat renal cytosolic fractions
contained fewer specific ligand-binding sites than observed in the
duodenum. However, as in the intestine, the kidneys obtained
from rats with idiopathic hypercalciuria contained twice the
number of cytosolic binding sites as did those from control
animals. The affinity of the receptor for 1,25(OH)2D3 was similar
in both groups. No experiments were performed in bone as target
cells. According to these authors, the accumulation of both
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intestinal and renal VDR in the idiopathic hypercalciuric rat
suggests that the increased receptor number is more generalized,
although additional measurements in other tissues are required to
definitively answer this question.
DR. MADIAs: In your judgment, does it serve any practical
purpose to work up a patient with idiopathic hypercalciuria for the
presence of fasting versus absorptive hypercalciuria?
DR. WEISINGER: Although this initial classification of hypercal-
ciuria stimulated research in this field, at present I do not favor
subjecting hypercalciuric patients to a week on a low-calcium diet
followed by a calcium absorption test. I strongly believe that the
absorptive and fasting forms of hypercalciuria are part of the same
pathophysiologic derangement, with both groups of patients hav-
ing increased intestinal absorption of calcium. The number of
patients who fit into the criteria for renal leak is exceedingly small,
and there is no practical utility in separating the patients into
these two subgroups. All the patients will benefit from sodium and
protein restriction; if the hypercalciuria persists, the use of a
thiazide or chlorthalidone is indicated, We also have said today
that a calcium-restricted diet could induce severe iatrogenic
problems, besides not reducing the stone formation rate. The use
of sodium cellulose phosphate therapy in absorptive hypercalci-
uria could induce a severe negative calcium balance and parathy-
roid stimulation, and cause magnesium depletion, as well as
induce secondary hyperoxaluria by reducing divalent cation-
oxalate complexation, thus making more oxalate available for
intestinal absorption. For these reasons, it is no longer necessary
to distinguish the various types of hypercalciuria. I treat hyper-
calciuric patients initially with dietary sodium and protein restric-
tion and an increased fluid intake. If the urinary oxalate is
elevated, I reduce oxalate-rich foods. In the case of associated
hypocitraturia, I start potassium citrate because it inhibits calcium
oxalate crystallization. If the hypercalciuria persists, I utilize a
thiazide diuretic, usually with a potassium-sparing agent such as
triamterene or amiloride.
DR. NESTOR SCHOR (Department of Medicine, Division of Ne-
phrology, Escola Paulista de Medicina, São Paulo, Brazil): Do you
have additional data about protein intake and osteopenia? We did
not find differences in protein intake between hypercalciuric
patients with and without osteopenia [951.
DR. WEISINGER: We have not evaluated the dietary protein
intake in relationship to the degree of osteopenia, but we know
that high protein intake theoretically could lead to decreased
bone mass by increasing urinary calcium excretion [5] and by the
effect of acidosis on bone, which favors osteoporosis [96].
DR. SCHOR: Have you seen any data with new markers of bone
resorption like pyridinoline?
DR. WEISINGER: I have seen no data on pyridinoline crosslink
excretion in hypercalciuric patients.
DR. ITA PFEFERMAN HEJLBERG (Department of Medicine, Divi-
sion of Nephrology, Escola Paulista de Medicina): Is there any
effect of thiazides on cytokine production in osteoporotic hyper-
calciuric patients?
DR. WEIsINGER: We are conducting a study to evaluate the
effect of thiazides on cytokine production in hypercalciuric pa-
tients. Preliminary analysis shows no effect of the thiazides upon
cytokine production. Evidence does suggest that long-term thia-
zide use causes calcium retention [97]. Epidemiologic data from
the same group demonstrated that long-term use of thiazides in
hypertensive patients reduced the incidence of femoral neck
fractures when compared with hypertensive patients controlled
with other medication. Perrone et al have demonstrated that bone
mineral content improved in children whose hypercalciuria was
controlled with thiazide diuretics [98]. For these reasons, I suggest
that we use a thiazide, plus the other recommendations I men-
tioned previously, in patients with minimal bone loss. If the
patient is postmenopausal, I advise starting hormone replacement
therapy. In recurrent stone formers, I suggest a normal calcium
diet, but the oral calcium intake should not exceed 1000 mg/day.
In male patients with severe osteoporosis or women with contra-
indications for estrogen replacement therapy, the use of antire-
sorptive therapy, especially biphosphonates, should be consid-
ered. Careful monitoring of the blood and urine chemistries and
the bone mineral content should continue.
DR. Luis JUNCOS (Department of Medicine, Division of Nephrol-
ogy, Universidad Nacional de Córdoba, Córdoba, Argentina): What
is the effect of biphosphonates on urinary calcium excretion in
patients with idiopathic hypercalciuria compared with individuals
who excrete calcium normally?
DR. WEISINGER: I am not aware of any work on this subject, but
it would be an interesting research protocol.
DR. MADIAS: Regarding the effect of prostaglandins on bone
resorption, have careful studies documented whether nonsteroi-
dal anti-inflammatory drugs decrease calciuria in sodium-re-
stricted patients?
DR. WEISINGER: Prostaglandin synthesis inhibitors have been
used in patients with hypercalciuria and in children with the
so-called hyperprostaglandin E syndrome. Filliponi et al assessed
the effect of these drugs by sequentially administering sodium
diclofenac and sulindac, an NSAID inactive on renal prostaglan-
din synthetase, each for 2 weeks [71]. Diclofenac reduced urinary
calcium excretion in patients with idiopathic hypercalciuria with
either normal or elevated fasting urinary calcium, whereas it was
ineffective in normocalciuric stone formers. Sulindac was effective
only in patients with fasting hypercalciuria. These data suggest
that prostaglandins play an important role in idiopathic hypercal-
ciuria. In children with hyperprostaglandin E syndrome, a neona-
tal variant of Bartter's syndrome with hypercalciuria, nephrocal-
cinosis, and osteopenia, although the urinary calcium level did not
correlate with urinary PGE2 excretion, treatment with indometh-
acm reduced the urinary calcium significantly, although not to
normal levels [71, 99]. After discontinuation of the indomethacin,
urinary calcium rebounded to previous values. This study suggests
that NSAIDs could decrease the prostaglandin-dependent part of
hypercalciuria and concomitantly suppress the prostaglandin-
mediated bone resorption process. I am not aware of careful,
controlled studies in sodium-restricted patients that further ad-
dress the mechanism of the hypocalciuric effect of NSAIDs.
Finally, I think we need more data before we routinely start using
these drugs, which have a number of side effects, in hypercalciuric
patients.
DR. PABLO MASSARI (Associate Professor of Medicine, Univer-
sidad Católica de Cordoba, Cordoba, Argentina): Does IL-i have a
direct effect on the renal tubular handling of calcium? Does high
protein intake induce increased IL-la production?
DR. WEISINGER: I have not seen any data supporting an effect of
IL-i on the renal tubular handling of calcium. As I mentioned,
high protein intake increases the severity of hypercalciuria. I do
not know whether this effect is mediated through increased IL-la
production.
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DR. MARTJNEZ-MALDONADO: Since some rats have increased
vitamiri-D receptor number [26] and possibly increased expression
of IL-irs or TNF-a in peripheral mononuclear cells, could it be
possible to block these abnormalities with dexamethasone or
other steroids, which might stop both these mechanisms and
improve overall bone turnover and calcium balance?
DR. WEISINGER: Glucocorticoids decrease intestinal calcium
absorption, and at the same time inhibit the proliferation of T-cell
lymphocytes, the production of T-cell growth factor, and the
production of macrophage migration inhibitory factor. For these
reasons, glucocorticoids could be used in granulomatous diseases
that cause hypercalciuria and hypercalcemia, such as sarcoidosis.
Nevertheless, the long-term effects of these drugs on bone mineral
could be detrimental. Glucocorticoids inhibit bone formation by
inhibiting cell replication. Such an effect on pre-osteoblasts would
impair osteoblast renewal, and bone growth would progressively
decrease.
DR. CESAR BOGAD0: (Established Investigator, Instituto de Inves-
tigaciones Metabólicas, Buenos Aires, Argentina): You and others
have found no differences in 1,25(OH)2D3 levels between hyper-
calciuric and normocalciuric renal stone formers. Since the syn-
thesis of the vitamin-D receptor is regulated by 1,25(OH)2D3
itself, how do you explain the increase in the number of vitamin D
receptors in hypercalciuric rats?
DR. WEIsINGER: The magnitude of the 1,25(OH)2D3 action is
related to the VDR content and functional VDR-1,25(OH)2D3
complexes or receptor occupancy. In vitro, 1,25(OH)2D3 itself
induces a homologous upregulation of the VDR [1001. Li et al
have suggested that an increased number of VDR without a
change in the circulating levels of 1,25(OH)2D3 number also
increases the number of VDR-1 ,25(OH)2D3 complexes, thereby
stimulating duodenal net calcium transport [26]. These authors
also suggested that increased intestinal VDR content in idiopathic
hypercalciuric rats is a phenotypic marker for intestinal calcium
hyperabsorption. Whether these conditions also are true in hu-
mans remains to be determined.
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